Literature DB >> 7397941

A sensitive radioimmunoassay for vincristine and vinblastine.

V S Sethi, S S Burton, D V Jackson.   

Abstract

A rapid, sensitive and highly reproducible radioimmunoassay (RIA) has been devised for vincristine and vinblastine. These alkaloids bind to the antiserum very tightly with an association constant (Ka) of 5 x 10(9) M-1 as determined by Scatchard analysis. The kinetic association constant of the alkaloids, as determined by the 'on' and 'off' rates at 4 degrees C, is 30-fold higher than the Scatchard analysis value. At 4 degrees C, 80% of the alkaloid is bound to the antiserum within 20 min, and the remaining 20% reaches an equilibrium within 48-72 h. In the RIA procedure the amount of the alkaloid (1-2 ng) needed to compete for 50% binding remains unchanged when the reaction mixtures are incubated for 2, 4, or 20 h. By a modification of the RIA procedure, where the antiserum is first allowed to react with the unlabeled alkaloid followed by addition of the radiolabeled alkaloid, sensitivity of the assay has been increased five- to tenfold. Other drugs, such as adriamycin, CCNU, methyl CCNU, cyclophosphamide, 5-fluorouracil, heparin, hydrocortisone, prednisone, and nitrogen mustard do not interfere with the assay. This assay can thus be used to determine vincristine or vinblastine levels in 5 x 10(-10)--10(-9) M concentrations in biological fluids.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7397941     DOI: 10.1007/bf00254016

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  The pharmacokinetics of 4-acetyl tritium vinblastine in two patients.

Authors:  R J Owellen; C A Hartke
Journal:  Cancer Res       Date:  1975-04       Impact factor: 12.701

2.  The pharmacokinetics of [3H]-vincristine in man.

Authors:  R A Bender; M C Castle; D A Margileth; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

3.  Pharmacokinetics of vindesine and vincristine in humans.

Authors:  R J Owellen; M A Root; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

4.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

5.  Distribution and excretion of (3H)vincristine in the rat and the dog.

Authors:  M C Castle; D A Margileth; V T Oliverio
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

6.  Pharmacological studies with vinblastine in the dog.

Authors:  W A Creasey; A I Scott; C C Wei; J Kutcher; A Schwartz; J C Marsh
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

7.  Biliary excretion of vincristine.

Authors:  D V Jackson; M C Castle; R A Bender
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

8.  Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.

Authors:  C J Barnett; G J Cullinan; K Gerzon; R C Hoying; W E Jones; W M Newlon; G A Poore; R L Robison; M J Sweeney; G C Todd; R W Dyke; R L Nelson
Journal:  J Med Chem       Date:  1978-01       Impact factor: 7.446

9.  Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys.

Authors:  S M El Dareer; V M White; F P Chen; L B Mellet; D L Hill
Journal:  Cancer Treat Rep       Date:  1977-10

10.  Radioimmunoassay of vinblastine and vincristine.

Authors:  J D Teale; J M Clough; V Marks
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

View more
  12 in total

1.  Hepatic intra-arterial infusion of vincristine.

Authors:  D V Jackson; F Richards; C L Spurr; T R Long; D A Rardin; D A Albertson; J M Sterchi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

2.  A phase I and pharmacokinetic study of intravenous vinzolidine.

Authors:  C W Taylor; S E Salmon; W G Satterlee; A B Robertone; T M McCloskey; M T Holdsworth; P M Plezia; D S Alberts
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

3.  Pharmacokinetics of vindesine bolus and infusion.

Authors:  D V Jackson; V S Sethi; T R Long; H B Muss; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine.

Authors:  J A Young; S B Howell; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.

Authors:  V S Sethi; P Surratt; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 7.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

8.  Clinical pharmacology of vinzolidine.

Authors:  W Kreis; D R Budman; P Schulman; J Freeman; A Greist; R L Nelson; M Marks; L Kevill
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Continuous intravenous infusion of vinca alkaloid using a subcutaneously implanted pump in a canine model.

Authors:  D V Jackson; M L Barringer; D L Rosenbaum; T R Long; J M Sterchi; W Meredith; V S Sethi; E J Modest; H B Wells; C L Spurr; M C Castle
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Pharmacokinetics of vincristine sulfate in children.

Authors:  V S Sethi; J C Kimball
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.